Candel Therapeutics, Inc.

Freedom Broker has initiated on Candel Therapeutics, which&nbsp;develops immunotherapies for cancer patients, and estimates the stock has upside of more than 100%. The company has low debt and a large cash pile to finance operations, Freedom Broker points out.

Freedom Broker initiates with 'buy' on cancer therapy developer Candel Therapeutics

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Freedom Broker has issued a trade idea on the biotech Viking Therapeutics. The company is expected to present fresh data from clinical trials of its main weight-loss drug, and historically, as Freedom Broker points out, the stock rises ahead of these events.

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

ProKidney Corp.

Biotech ProKidney, which develops a cell therapy platform for the treatment of multiple chronic kidney diseases, rose sixfold yesterday, July 8, to reach a market capitalization of $1.8 billion. The trigger was successful clinical trial results of its drug, but analysts are cautious.&nbsp;

Biotech ProKidney soars 500% after positive trial results, but analysts are cautious

Ocugen, Inc.

Carisma Therapeutics, Inc.

Gene and cell therapy biotech Ocugen has <a href="https://finance.yahoo.com/news/carisma-therapeutics-orthocellix-enter-definitive-113000554.html">agreed</a> to a merger with Carisma Therapeutics, a tiny <a href="https://carismatx.com/">developer</a> of novel therapies for fibrosis and cancer. Ocugen will transfer its regenerative medicine division and in return will get 90% of the new company. Noble Capital Markets&nbsp;<a href="https://www.channelchek.com/news-channel/ocugen-ocgn-merger-agreement-moves-neocart-into-a-new-company">sees</a>&nbsp;more than 670% upside for Ocugen.&nbsp;

Biotech Ocugen to spin off regenerative medicine division; Noble confirms 670% upside

SS Innovations International, Inc.

SS Innovations, a developer of surgical robotic technologies, soared 42% yesterday, June 18. That is how investors reacted to the news of the successful completion of its first robotic cardiac surgery in the Western Hemisphere. The stock has been trading on the Nasdaq for only about two months.

Surgical robot maker SS Innovations soars after first cardiac surgery in Americas

Sarepta Therapeutics, Inc.

Quotes of Sarepta Therapeutics, a small-cap developer of precision genetic medicines to treat rare neuromuscular and central nervous system diseases, plummeted 42% yesterday, June 16, to hit a nine-year low. The company reported the death of the second teenager in three months who was taking its drug to treat muscular dystrophy. In addition, Sarepta has withdrawn its revenue guidance for 2025 as it may be forced to pull the drug from the market, analysts warn.

Sarepta tanks after death of second teen taking its gene therapy; outlook 'cloudy'

Altimmune, Inc.

Merck & Co., Inc.

The company's lead candidate could treat both obesity and alcohol use disorder

Freedom Broker issues short-term idea to buy biotech Altimmune ahead of trial results

Vera Therapeutics, Inc.

Otsuka Holdings Co., Ltd.

Shares of small-cap biotech Vera Therapeutics have plummeted nearly 28% in the last two sessions, after a huge jump in the days before. Last week, Vera and one of its main competitors published clinical trial data for drugs fighting the same disease. Vera took the worst of it, but analysts say this is far from the end of the story.

Vera Therapeutics soars on positive test data, only to plunge after competitor trial

The stock price of Sana Biotechnology surged 160% on January 8, with intraday gains exceeding 300%. The company <a href="https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-announces-positive-clinical-results-type-1?utm_source=in_materials">announced</a> a groundbreaking achievement: successfully transplanting insulin-producing pancreatic cells into a patient with type 1 diabetes without the need for immunosuppression. Sana hopes this breakthrough will revolutionize the nearly <a href="https://www.mordorintelligence.com/ru/industry-reports/diabetes-drugs-market?utm_source=in_materials">$100 billion</a> diabetes treatment market. Analysts see potential for the company’s shares to more than double in value.

Shares of Sana soar following breakthrough in diabetes therapy trials

Shares of BioHarvest Sciences, which uses its proprietary botanical synthesis technology to develop therapeutic solutions, advanced close to 12% on the Canadian Securities Exchange (CSE) and almost 14% over the counter in New York on Thursday, November 7. The gains followed the company’s announcement that Nasdaq had approved its listing on its primary burse. BioHarvest’s management believes the listing will broaden its potential shareholder base, increase liquidity, and enhance its public profile compared to the over-the-counter market.

Biotech company BioHarvest advances following Nasdaq listing approval

Quotes on shares of ProMIS Neurosciences, a developer of drugs for Alzheimer's disease and amyotrophic lateral sclerosis (ALS), <a href="https://www.nasdaq.com/market-activity/stocks/pmn">dropped</a> more than 20% on Friday, July 26. The company announced a <a href="https://www.promisneurosciences.com/investors/news-events/press-releases/detail/224/promis-neurosciences-announces-up-to-122-7-million-private">private placement</a> for up to $122.7 million, along with <a href="https://www.promisneurosciences.com/investors/news-events/press-releases/detail/225/promis-neurosciences-reports-positive-top-line-data-from">positive</a> data from clinical trials with healthy volunteers for its main drug candidate.

Alzheimer's drug developer ProMIS loses over 20% of market capitalization in a day

Shares of Citius Pharmaceuticals, a developer of drugs for bloodstream infections, lymphoma, and hemorrhoids, surged over 10% on Wednesday, July 10. This came after the company <a href="https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Details-Near-Term-Milestones-for-Late-Stage-Candidates/default.aspx">announced</a> that it had completed trials of one of its drugs and is close to commercially launching another. The company expects "strong momentum" if everything comes together. 